When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study

Lauren E Cain, Roger Logan, James M Robins, Jonathan A C Sterne, Caroline Sabin, Loveleen Bansi, Amy Justice, Joseph Goulet, Ard van Sighem, Frank de Wolf, Heiner C Bucher, Viktor von Wyl, Anna Esteve, Jordi Casabona, Julia del Amo, Santiago Moreno, Remonie Seng, Laurence Meyer, Santiago Perez-Hoyos, Roberto MugaSara Lodi, Emilie Lanoy, Dominique Costagliola, Miguel A Hernan, HIV-CAUSAL Collaboration

Research output: Contribution to journalArticle (Academic Journal)peer-review

177 Citations (Scopus)

Abstract

Most clinical guidelines recommend that AIDS-free, HIV-infected persons with CD4 cell counts below 0.350 × 10(9) cells/L initiate combined antiretroviral therapy (cART), but the optimal CD4 cell count at which cART should be initiated remains a matter of debate.
Original languageEnglish
Pages (from-to)509-515
Number of pages7
JournalAnnals of Internal Medicine
Volume154
Issue number8
DOIs
Publication statusPublished - 19 Apr 2011

Fingerprint Dive into the research topics of 'When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study'. Together they form a unique fingerprint.

Cite this